Omnicell (NASDAQ:OMCL) Updates Q2 Earnings Guidance

Omnicell (NASDAQ:OMCL) issued an update on its second quarter earnings guidance on Thursday morning. The company provided earnings per share guidance of $0.10-0.20 for the period, compared to the consensus earnings per share estimate of $0.27. The company issued revenue guidance of $250-260 million, compared to the consensus revenue estimate of $261.84 million. Omnicell also updated its FY24 guidance to $0.90-1.40 EPS.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $27.17 on Thursday. The business’s fifty day moving average price is $27.61 and its two-hundred day moving average price is $31.90. Omnicell has a fifty-two week low of $25.69 and a fifty-two week high of $77.14. The company has a current ratio of 2.52, a quick ratio of 2.22 and a debt-to-equity ratio of 0.48.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, February 8th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.22. The company had revenue of $258.85 million for the quarter, compared to analysts’ expectations of $256.00 million. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. Sell-side analysts anticipate that Omnicell will post 0.09 earnings per share for the current year.

Analyst Upgrades and Downgrades

OMCL has been the topic of several research analyst reports. Benchmark restated a buy rating and set a $38.00 target price on shares of Omnicell in a report on Tuesday. Barclays assumed coverage on Omnicell in a report on Wednesday, January 3rd. They issued an underweight rating and a $33.00 price target on the stock. Finally, Wells Fargo & Company decreased their price target on Omnicell from $28.00 to $26.00 and set an equal weight rating on the stock in a report on Friday, February 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock has an average rating of Hold and an average target price of $42.20.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.